MMJ Recs

MAY 3, 2024

With its program in full swing, thousands of patients across the state are benefiting from access to this alternative form of treatment. From chronic pain to PTSD, patients with qualifying medical conditions have found solace in medical marijuana where traditional treatments may have fallen short.

Marijuana 52

Marijuana Treatment Compliance Compliance 52

Veriheal

AUGUST 12, 2021

Patients who suffer from epilepsy , which affects some 3.4 Pharmaceutical CBD is currently a restricted prescription medication, and insurance coverage is often limited to only those patients with the specific approved indications. Researchers Analyzed Survey Results from 280 Epilepsy Patients.

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

DECEMBER 27, 2019

A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Cognizance VCT enables the generation of cost-effective quality data with ethical consent, on par with academic studies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. COMP360 psilocybin therapy has now been given to 233 patients, exceeding 216 target. On track to report top-line data by end of 2021. million, or $0.79 LONDON, Aug.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g.,

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

CannaMD

MAY 19, 2020

Our initial data suggest that some C. Note: Study extracts were applied via media. CannaMD will continue to keep patients updated as more information becomes available. But what does marijuana have to do with ACE2? Writing that “the extracts of our most successful and novel high-CBD C. Find a Medical Marijuana Doctor.

Research and Development 131

Research and Development Sativa Marijuana Extraction 131

Cannabis Law Report

JULY 22, 2021

. “By acquiring traditional healthcare assets and subsequently layering in alternative medicines and psychedelic therapies as regulations develop, Levitee will have direct and immediate access to a much broader patient population. Levitee Media Contact. media@leviteelabs.com. About Levitee Labs. ir@leviteelabs.com.

eCommerce 105

eCommerce Therapy Media Access 105

CannaMD

NOVEMBER 6, 2019

Today, both patient experience and modern scientific research support claims of medical marijuana’s effectiveness for pain management. Questions included any changes in personal levels of opioid use when marijuana was also used, and the reasons why patients were substituting marijuana for prescription pain medications.

Marijuana 87

Marijuana Patients Clinical Trials Data 87

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JULY 29, 2021

We want to be an industry leader in preventing negative side effects during treatment and believe this can be of benefit to the entire industry.” There have been various individual studies of the condition, but the Ehave study could be the largest patient study to date. Media Inquiries: Gabe Rodriguez. Contact: Ehave Inc.

Research and Development 105

Research and Development Conditions Data Patients 105

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. “Our fourth quarter and full year results for 2019 reflect an exceptional launch year for Epidiolex.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JULY 24, 2019

But it is important that access to it is delivered in a way that fits in with other treatment options. Our clinics are based on the premise that patients are treated by our world-renowned specialists in the relevant condition.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

CannaMD

AUGUST 19, 2020

While COVID-19 can be deadly, the World Health Organization (WHO) stresses that most patients experience mild cases and/or survive: Most people who get COVID-19 have mild or moderate symptoms and can recover thanks to supportive care. ” And their alternative strategy of choice? But what does marijuana have to do with ACE2?

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Canna Law Blog

APRIL 13, 2019

The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.” Specifically, the agency fears that.

CBD 91

CBD Safety Topical Food 91

Cannabis Law Report

DECEMBER 14, 2021

The products launched under its flagship medical Ceed brand and are comprised of four formulations that will be available for patients throughout the UK when prescribed by a specialist consultant. Columbia Care’s mission has always been to provide patients with access to the highest quality, safest medicinal cannabis products available.

Extraction 52

Extraction Patients Medicine Tincture 52

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU. . Media Contact: media@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Freedom Leaf

JANUARY 4, 2018

After months of development, my partner and I built and successfully launched the beta for our cannabis data-analytics software, Jade Insights. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making. ” JOHN KAGIA. ” OPHELIA CHONG.

Data 60

Data Policy Media Cannabis 60

The Blunt Truth

AUGUST 13, 2019

To understand the breadth of issues and gather data on safety we have conducted a public hearing, reviewed the medical literature, and have an open public docket.”. The FDA is collecting data to fill these gaps. In 2019, the FDA issued warning letters to four companies marketing and selling CBD products.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”.

CBD 40

CBD Research and Development Safety Therapy 40

Cannabis Law Report

FEBRUARY 17, 2022

WORCESTER – The Cannabis Control Commission (Commission) is alerting patients and consumers to its quarantine order (Order), issued October 18, 2021, mandating that ACK Natural, LLC, a colocated medical- and adult-use licensee, recall all products with unverifiable mycotoxin test results sold to its consumers and patients.

Marijuana 52

Marijuana Seed-To-Sale Safety Patients 52

Cannabis Law Report

JULY 20, 2019

In New Jersey, there are nearly 50,000 registered medical marijuana patients and only six Alternative Treatment Centers (ATCs) currently operating. authorizes home delivery to patients. authorizes home delivery to patients. Ability to meet the overall health needs of qualified patients and safety of the public.

Law 40

Law Marijuana Education Cultivation 40

Cannabis Law Report

OCTOBER 29, 2021

We expect to report this data as it becomes available and after submission to the FDA. The Company believes that this may be the first such filing using low doses of a natural phytocannabinoid, THC, on patients suffering from Alzheimer’s disease. social media: www.igcinc.us / www.igcpharma.com. India Globalization Capital, Inc.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JULY 23, 2019

Some states require mandatory warning statements in advertisements for medical cannabis. required to provide other warnings that may be needed by the commission. a playground, recreation centre, library or public park. a playground, recreation centre, library or public park.

Law 40

Law Clinical Trials CBD Edibles 40

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. Silver Spike Acquisition Corp. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52